Literature DB >> 1469637

Whole body and brain distribution of [3H]cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration.

S J Weber1, D L Greene, V J Hruby, H I Yamamura, F Porreca, T P Davis.   

Abstract

The route of administration of a given drug can have a significant influence upon whole body distribution. The present study examined whole body distribution of the delta opioid receptor-selective peptide [3H]DPDPE in male CD1 mice after administration by several routes. Additionally, we describe regional brain distribution of [3H]DPDPE after i.v. administration with and without pretreatment with naloxone or the selective delta receptor antagonist naltrindole. Finally, characterization of the inherent enzymatic stability of DPDPE was also examined. Intravenous administration results in a significantly large amount of [3H]DPDPE in the small intestine and flush at 15 and 30 min postadministration, suggesting rapid biliary excretion. The highest level in the brain after i.v. administration occurred at 60 min (0.08%). After i.p. and s.c. administration, large amounts of [3H]DPDPE were found in the small intestine and flush, but not until 60 min postadministration, suggesting a slower rate of absorption from the site of administration. The i.p. and s.c. groups' brain levels peaked at 120 min (0.07 and 0.09%, respectively). The highest levels in the brain after p.o. administration were seen at 240 min (0.03%). Examination of regional brain distribution data showed no significant difference in the levels of [3H]DPDPE between brain regions at any time point studied. However, naloxone pretreatment resulted in significant reductions of [3H]DPDPE in all brain regions at 5 and 10 min. Naltrindole pretreatment resulted in significant reductions in the frontal cortex and striatum at 5 and/or 10 min postadministration, but had no effect on [3H]DPDPE levels in cerebellum, hippocampus or brain stem.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469637

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

Review 2.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 3.  Peptides at the blood brain barrier: Knowing me knowing you.

Authors:  Thomas P Davis; Thomas J Abbruscato; Richard D Egleton
Journal:  Peptides       Date:  2015-04-30       Impact factor: 3.750

4.  Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 5.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

6.  Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

7.  In vitro and in vivo efficacy of a potent opioid receptor agonist, biphalin, compared to subtype-selective opioid receptor agonists for stroke treatment.

Authors:  Li Yang; Mohammad R Islam; Vardan T Karamyan; Thomas J Abbruscato
Journal:  Brain Res       Date:  2015-03-20       Impact factor: 3.252

Review 8.  Peptides and the blood-brain barrier.

Authors:  William A Banks
Journal:  Peptides       Date:  2015-03-21       Impact factor: 3.750

9.  Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.

Authors:  William A Banks; Susan A Farr; John E Morley; Kathy M Wolf; Valeria Geylis; Michael Steinitz
Journal:  Exp Neurol       Date:  2007-05-22       Impact factor: 5.330

10.  Tyr1-ψ[( Z)CF═CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin.

Authors:  Ryan A Altman; Krishna K Sharma; Lian G Rajewski; Paul C Toren; Michael J Baltezor; Mohan Pal; Somnath N Karad
Journal:  ACS Chem Neurosci       Date:  2018-04-19       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.